Perioperative Vericiguat in Patients Undergoing Cardiovascular Surgery

The purpose of this study is to evaluate the efficacy and safety of perioperative vericiguat in patients undergoing cardiovascular surgery. Patients at high risk of heart failure or with confirmed cardiac dysfunction will be randomly assigned to receive either vericiguat plus standard of care or standard of care alone. The primary objective is to determine whether perioperative administration of vericiguat can reduce (I) the Incidence of Early Postoperative Hemodynamic Deterioration or Clinically Significant Myocardial Injury; (II) Incidence of Major Sterile Inflammation-Related Organ Injuries (MSIRI), and the incidence of Major Adverse Cardiovascular Events (MACE) within 12 months after surgery.

NCT Number	NCT07594509
Lead Sponsor	Nanjing Medical University Collaborators: Beijing Anzhen Hospital, The Affiliated Hospital of Qingdao University, Changzhou First People's Hospital, The First Affiliated Hospital of Guangzhou Medical University, The First Affiliated Hospital of Bengbu Medical University, West China Hospital, Shanghai East Hospital, China
Conditions	Cardio Vascular Disease, Cardiopulmonary Bypass
Enrollment	600 participants
Start Date	2026-05-31
Primary Completion	2028-12-31 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-18